Sunitinib: the antiangiogenic effects and beyond.

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Sunitinib is a multitargeted tyrosine kinase inhibitor.
• It is a primary treatment for metastatic renal cell carcinoma (mRCC).
• Sunitinib targets key receptors involved in angiogenesis and cancer progression.

Purpose of the Study:

• To review the efficacy and mechanisms of sunitinib in mRCC treatment.
• To discuss resistance mechanisms, toxicities, and emerging roles of sunitinib.
• To explore potential combination therapies for enhanced outcomes.

Main Methods:

• Literature review of sunitinib's mechanism of action.
• Analysis of clinical data regarding efficacy and side effects.
• Exploration of preclinical and clinical studies on resistance and novel applications.

Main Results:

• Sunitinib effectively inhibits receptor tyrosine kinases (VEGFR, PDGFR, cKIT) crucial for angiogenesis.
• Mechanisms of resistance are not fully understood but involve intrinsic and acquired factors.
• Sunitinib exhibits manageable side effects but can cause serious toxicities requiring dose adjustments.
• Emerging evidence suggests an immunomodulatory role for sunitinib, potentially mediated by cKIT.

Conclusions:

• Sunitinib is a cornerstone therapy for mRCC, targeting key angiogenic pathways.
• Understanding resistance and toxicity is critical for optimal patient management.
• Investigating sunitinib's immunomodulatory effects and combination therapies holds promise for future cancer treatments.